When Angelina Jolie revealed in a 2013 New York Times op-ed that she had undergone a preventive double mastectomy, the news sent shockwaves through the medical community and beyond. The acclaimed actress and director made the deeply personal decision to have both breasts removed despite having no cancer diagnosis, choosing instead to proactively address a significantly elevated genetic risk. Her choice brought the complex topics of genetic testing, hereditary cancer syndromes, and preventive surgery into the global spotlight, sparking conversations that continue to influence women’s health decisions today.
The Genetic Factor: Understanding BRCA1 and BRCA2
Jolie’s decision was rooted in genetics. She carries a mutation in the BRCA1 gene, a discovery that meant her lifetime risk of developing breast cancer was dramatically higher than that of the average woman. BRCA1 and its counterpart BRCA2 are tumor suppressor genes; when functioning normally, they help repair damaged DNA and prevent uncontrolled cell growth. However, inherited mutations in these genes impair this protective function, leaving individuals far more susceptible to certain cancers.
The statistics are striking. In the general population, approximately 12 out of every 100 women—12 percent—will develop breast cancer at some point in their lives. Among women with a harmful BRCA1 or BRCA2 mutation, that number jumps to 60 out of 100, or 60 percent. These mutations also significantly increase the risk of ovarian cancer, and men carrying them face elevated risks of breast cancer as well.
For Jolie, the risk was compounded by family history. Her mother, actress Marcheline Bertrand, died of ovarian cancer at age 56, a loss that profoundly shaped Jolie’s approach to her own health. Women who have at least two close relatives—mothers, sisters, or daughters—with breast or ovarian cancer are considered at much higher risk, making them strong candidates for genetic testing and potential preventive measures.
What Is Prophylactic Mastectomy?
The procedure Jolie underwent is formally known as a prophylactic double mastectomy. Unlike a mastectomy performed after a cancer diagnosis, prophylactic mastectomy involves removing both healthy breasts to prevent cancer from ever developing. Some women choose this route when a tumor is found in one breast, opting to remove both the affected and the healthy breast simultaneously. Others, like Jolie, undergo the procedure preemptively before any cancer has been detected.
Between 1998 and 2005, the use of prophylactic mastectomy doubled, according to research published in Current Oncology Reports, and the trend has continued. Several factors drive this increase. Widespread availability of genetic testing for BRCA1 and BRCA2 has allowed more women to understand their inherited risks. Additionally, high-profile cases like Jolie’s—as well as those of Sharon Osbourne, who underwent a preventive mastectomy due to high risk, and Christina Applegate, who had a double mastectomy after a tumor was found in one breast—have raised awareness about the option.
The Decision-Making Process: Weighing Risks and Benefits
Choosing prophylactic mastectomy is an intensely personal decision that requires careful consideration of medical, emotional, and practical factors. On one side of the equation, the surgery dramatically reduces breast cancer risk—by approximately 90 to 95 percent for women with BRCA mutations. For those facing an already elevated risk, this reduction can provide profound peace of mind.
However, the decision is far from simple. All surgery carries inherent risks, including complications from anesthesia, infection, and bleeding. Mastectomy itself requires significant recovery time, and many women who choose the procedure also opt for breast reconstruction, which involves additional surgeries and extended healing. The physical toll, while typically temporary, is considerable.
Psychological factors weigh heavily as well. A University of Michigan study presented at the American Society of Clinical Oncology meeting found that nearly three-quarters of women who opted for prophylactic mastectomy were actually at very low risk of developing cancer in the healthy breast. According to the researchers, these women did not have strong medical justifications and were “not expected to benefit in terms of disease-free survival.”
Yet the study did not conclude these decisions were wrong. Instead, it highlighted the complex emotional calculus behind the choice. Approximately 90 percent of women who had preventive mastectomy reported being “very worried” about facing cancer again, and the surgery effectively alleviated that fear. A subsequent study from the University of Pittsburgh reinforced that most women who undergo prophylactic mastectomy are glad they did and would recommend the procedure to others in similar circumstances.
The Importance of Accurate Information
The University of Michigan research underscored a critical point: women diagnosed with breast cancer or facing high genetic risk need more and better information to make informed choices. Understanding the actual likelihood of developing cancer in the healthy breast, as well as the true risks and benefits of prophylactic surgery, is essential. Without accurate data, fear and anxiety can drive decisions that may not align with medical necessity.
Taking time to process the decision is equally vital. Consulting with trusted and knowledgeable experts—including genetic counselors, oncologists, and reconstructive surgeons—helps ensure that women have a complete picture before moving forward. Having as much information as possible before choosing prophylactic mastectomy can be as empowering as the decision itself.
A Legacy of Awareness and Advocacy
Jolie’s decision to share her story publicly was itself an act of advocacy. By writing about her experience in the New York Times, she transformed a private medical choice into a public conversation about genetic risk, preventive medicine, and women’s autonomy over their health. Her op-ed encouraged countless women to explore their own family histories, consider genetic testing, and have more informed discussions with their doctors.
The impact extended beyond individual awareness. Jolie’s openness helped destigmatize a procedure that was, at the time, still relatively unfamiliar to the general public. She framed her decision not as one of fear, but of empowerment—a proactive step to spend more time with her children and to take control of her future.
For women today facing similar decisions, the landscape is richer with resources than it was a decade ago. Genetic testing is more accessible, counseling services are more widely available, and the medical community has deeper insights into risk assessment and surgical outcomes. Yet the core challenge remains: balancing medical facts with personal values, and making a choice that aligns with both physical health and emotional well-being.
Whether or not prophylactic mastectomy is the right path depends on individual circumstances, including genetic profile, family history, and personal risk tolerance. For some women, the benefits clearly outweigh the risks. For others, less invasive options like enhanced screening, chemoprevention, or lifestyle modifications may be more appropriate. The key is having access to accurate information, expert guidance, and the time and support needed to make a fully informed decision.
Angelina Jolie’s story serves as a powerful reminder that knowledge is a form of agency. By confronting her genetic risk head-on and sharing her journey, she helped illuminate a path that many women might otherwise have walked alone. Her legacy in this realm is not just about the choice she made, but about the conversations she started—conversations that continue to empower women to take charge of their health, armed with information and supported by a community that understands the weight of the decision.